parkinson's disease (PD) is a progressive neurodegenerative disorder, and development of disease-modifying treatment is still an 'unmet medical need. Considering the implication of free iron(II) in PD, we report here the design and characterization of a novel hybrid iron chelator, (-).12 (D-607) as a multitarget.directed ligand against PD. Binding and functional assays at dopamine D-2/D-3 receptors indicate potent agonist activity of (-).12. The molecule displayed an efficient preferential iron(II) chelation properties along with poient in vivo activity in a reserpinized PD animal model. The compound also rescued PC12 cells from toxicity induced by iron delivered intracellularly in a dose-dependent manner. However, Fe3+ selective dopamine agonist 1 and a well-known antiparkinsonian drug pramipexole produced little to no neuroprotection effect under the same experimental condition. These observations strongly suggest that (-).12 should be a promising multifunctional lead molecule for a viable symptomatic and disease modifying therapy of PD.